Association between the systemic treatment of psoriasis and cardiovascular risk

Shi, Liqing; Lian, Ni; Sun, Junran; Liu, Lihao; Chen, Min

doi:10.1097/cm9.0000000000001249

Cited by 7 publications

(9 citation statements)

References 11 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, anti-TNF treatment, but not anti-IL17, anti-IL12 or anti-IL23 treatments, can induce body-weight increase in patients with psoriasis (Esposito et al, 2009, Gisondi et al, 2013, Gisondi et al, 2008a, Patsalos et al, 2020, Shi et al, 2021, Wu et al, 2020, indicating that TNFα may play a unique role in suppressing adipocyte growth. Indeed, TNFα is known to inhibit adipogenesis and induce adipocyte lipolysis (Cawthorn and Sethi, 2008), and therefore it is likely that TNF blockage may promote J o u r n a l P r e -p r o o f 16 weight gain by restoring adipogenesis and inhibiting lipolysis.…”

Section: Psoriasis and Adipocytokines: Il6 Il1β And Tnfαmentioning

confidence: 99%

“…Etanercept, a TNF-α‒blocking agent, has been proven to be effective in treating both PSO and obesity-related type 2 diabetes, suggesting that TNF-α may play a central role in regulating inflammation in PSO and obesity ( Hamminga et al., 2006 ). Interestingly, anti-TNF treatment but not anti‒IL-17, anti‒IL-12, or anti‒IL-23 treatments can induce a bodyweight increase in patients with PSO ( Esposito et al., 2009 ; Gisondi et al., 2013 , 2008a ; Patsalos et al., 2020 ; Shi et al., 2021 ; Wu et al., 2020 ), indicating that TNF-α may play a unique role in suppressing adipocyte growth. Indeed, TNF-α is known to inhibit adipogenesis and induce adipocyte lipolysis ( Cawthorn and Sethi, 2008 ), and therefore, it is likely that TNF blockage may promote weight gain by restoring adipogenesis and inhibiting lipolysis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity

et al. 2022

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Psoriasis and Adipocytokines: Il6 Il1β And Tnfαmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It is of utmost importance to recognise all the clinical aspects of the obese patient with psoriasis since it entails a series of metabolic complications [ 130 , 131 ], representing an evident difficulty in making therapeutic decisions, especially when it comes to systemic pharmacological therapy [ 45 ]. Since as mentioned above, the drugs used at high doses increase the adverse effects rate, mainly a rise in cardiometabolic complications.…”

Section: The Link Between Psoriasis and Obesitymentioning

confidence: 99%

“…Together with all this, biologic drugs have been the most disruptive approach to psoriasis management [ 131 , 134 ]. It is essential to highlight that a pleiad of clinical studies have shown that biological drugs approved to treat psoriasis and psoriatic arthritis are very effective.…”

Section: The Link Between Psoriasis and Obesitymentioning

confidence: 99%

Exploring the Links between Obesity and Psoriasis: A Comprehensive Review

Barros

Durán

Vera

et al. 2022

IJMS

View full text Add to dashboard Cite

Obesity is a major public health issue worldwide since it is associated with the development of chronic comorbidities such as type 2 diabetes, dyslipidemias, atherosclerosis, some cancer forms and skin diseases, including psoriasis. Scientific evidence has indicated that the possible link between obesity and psoriasis may be multifactorial, highlighting dietary habits, lifestyle, certain genetic factors and the microbiome as leading factors in the progress of both pathologies because they are associated with a chronic pro-inflammatory state. Thus, inflammation management in obesity is a plausible target for psoriasis, not only because of the sick adipose tissue secretome profile but also due to the relationship of obesity with the rest of the immune derangements associated with psoriasis initiation and maintenance. Hence, this review will provide a general and molecular overview of the relationship between both pathologies and present recent therapeutic advances in treating this problem.

show abstract

“…Interleukin-12 enhances the activation of T-helper-1, seen in the case of psoriasis and atherosclerosis, both. Hence this shows the relationship between the pathophysiology of psoriasis and atherosclerosis [4,5].…”

Section: Introductionmentioning

confidence: 69%

Psoriasis a Cause of Cardiovascular Diseases: A Review Article

Gupta¹,

Madke²

2022

Cureus

View full text Add to dashboard Cite

Psoriasis is a severe, chronic inflammatory disease characterized by erythematous plaques across the extensor surfaces of the skin. Psoriasis has been linked to a higher threat of vascular events like myocardial infarction and stroke. Other associated cardiovascular disorders in the case of psoriasis include building up atherosclerosis, non-ischemic dilated cardiomyopathy, and psoriatic arthritis. Individuals can use International Classification of Diseases (ICD-9) codes to identify cardiovascular disease/comorbidities and related risk factors. The relation between pathophysiology and mechanism of psoriasis and the building up of fat and cholesterol in or on the arterial walls makes the association between psoriasis and cardiovascular diseases more obvious. There is very little research on the adverse effect of systemic treatment of psoriasis on cardiovascular events. Treatment of psoriasis includes mainly biologics and systemic therapy, including methotrexate as a first-line drug. An indirect relation between psoriasis-arthritis and cardiovascular diseases is being noted. Various risk factors contribute to psoriasis and are associated with cardiovascular disease, including smoking, hypertension, and obesity. Personal management to decrease the threat to the cardiovascular system in case of psoriasis can be achieved by changing lifestyle, which includes exercising and avoiding smoking. The criteria for identifying metabolic syndrome are discussed in this review article. Figure Rating Scales (FRS) were used for studying the risk prediction of various cardiovascular diseases. Individuals with atherosclerosis, hypertension and diabetes mellitus type-2 are at a higher risk of developing cardiovascular events and multiple chronic conditions in the case of psoriasis; hence they are part of the population at risk.

show abstract

Association between the systemic treatment of psoriasis and cardiovascular risk

Cited by 7 publications

References 11 publications

Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity

Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity

Exploring the Links between Obesity and Psoriasis: A Comprehensive Review

Psoriasis a Cause of Cardiovascular Diseases: A Review Article

Contact Info

Product

Resources

About